Skip to content
Press Releases

ChromaDex Clinical Trial Studying NIAGEN® Well Underway, With Eight Additional Collaborative Human

IRVINE, Calif., July 20, 2016 (GLOBE NEWSWIRE) — ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced

today that the study of NIAGEN® – nicotinamide riboside is well underway having achieved 50% enrollment of its 140 total participants. This trial is examining the effective dose range of NIAGEN® to increase NAD+ and NAD+ metabolite concentrations in the body with consistent use over time. The study design is an 8-week, randomized, double-blind, placebo controlled parallel trial in 140 healthy adults ranging in age from 40-60. Study participants in the active group receive between 100-1000mg per day. Additional endpoints investigated include: C-reactive protein, total cholesterol, LDL, HDL and triglycerides and amino acid panels, NAD+levels in muscle, mitochondrial biomarkers, and the effects of NR on resting metabolic rate. Najla Guthrie, President and CEO of the contract research organization responsible for coordinating the trial, KGK Synergize Inc. commented, “We have been very pleased that enrollment has gone smoothly. If things continue along this path we would be on track to have results collected around December.”

In addition to this trial, there are eight other collaborative human studies actively underway which are sponsored by entities other than ChromaDex. There are also four additional human trials which are also estimated to begin sometime over the next 6 to 9 months. Frank Jaksch, Jr., CEO and co-founder of ChromaDex stated, “These are exciting times for the ChromaDex team and the scientific community at large. New research seems to be publishing on almost a weekly basis, further building the body of evidence around the effectiveness of NR and the importance of boosting NAD+. We look forward to sharing more about our study results in early 2017.”This is the second human clinical study sponsored by ChromaDex. The first human clinical trial announced in February 2015 demonstrated that a single oral dose of NIAGEN® is a safe, effective NAD+ precursor in humans.

https://globenewswire.com/news-release/2016/07/20/857425/0/en/ChromaDex-Clinical-Trial-Studying-NIAGEN-Well-Underway-With-Eight-Additional-Collaborative-Human-Studies-Active.html